Cargando…
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
CAR T-cell product quality and stemness (T(stem)) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete T(stem), affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validat...
Autores principales: | Dickinson, Michael J., Barba, Pere, Jäger, Ulrich, Shah, Nirav N., Blaise, Didier, Briones, Javier, Shune, Leyla, Boissel, Nicolas, Bondanza, Attilio, Mariconti, Luisa, Marchal, Anne-Laure, Quinn, David S., Yang, Jennifer, Price, Andrew, Sohoni, Akash, Treanor, Louise M., Orlando, Elena J., Mataraza, Jennifer, Davis, Jaclyn, Lu, Darlene, Zhu, Xu, Engels, Boris, Moutouh-de Parseval, Laure, Brogdon, Jennifer L., Moschetta, Michele, Flinn, Ian W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481129/ https://www.ncbi.nlm.nih.gov/pubmed/37249512 http://dx.doi.org/10.1158/2159-8290.CD-22-1276 |
Ejemplares similares
-
Model‐informed drug development for immuno‐oncology agonistic anti‐GITR antibody GWN323: Dose selection based on MABEL and biologically active dose
por: Ji, Yan, et al.
Publicado: (2022) -
Gut microbiome and CAR-T therapy
por: Abid, Muhammad Bilal, et al.
Publicado: (2019) -
Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
por: Hartmann, Jessica, et al.
Publicado: (2017) -
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022) -
CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)